Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

NCT05396105 is registered in ClinicalTrials.gov with Pharvaris Netherlands B.V. as lead sponsor.

NCT NCT05396105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05396105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
Lead sponsor
Pharvaris Netherlands B.V.
Phase
Phase 2/3
Overall status
Enrolling by invitation
Start date
December 28, 2022
Completion date
June 30, 2027
Enrollment
150 (estimated)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

c1 esterase inhibitor [c1-inh] deficiency, c1 esterase inhibitor deficiency, c1 esterase inhibitor, deficiency of, c1 inhibitor deficiency, hae with normal c1 esterase inhibitor, hereditary angioedema, hereditary angioedema (hae), hereditary angioedema - type 1, hereditary angioedema - type 2, hereditary angioedema - type 3, hereditary angioedema attack, hereditary angioedema type i, hereditary angioedema type i and ii, hereditary angioedema type ii, hereditary angioedema type iii, hereditary angioedema types i and ii, hereditary angioedema with c1 esterase inhibitor deficiency